Current Trials and Studies

Part of the mission of The LAM Foundation is to fund promising research. Our researchers need your help in order to conduct their research. Please see the open protocols below to see if you meet any of the requirements and find out how you can participate.

Study of the Disease Process of LAM - National Institutes of Health

Dr. Joel Moss
CLICK HERE for more details.

Helen Green Research Travel Grant

Patients who are participating at the protocol at the NIH may be eligible to apply for the Helen Green Research Travel Grant. To learn more about the grant and the guidelines, check out the Helen Green Research Travel Fund Guidelines. You can apply for the grant by clicking here.

If you have any questions regarding this travel grant, please contact Anne McKenna, Patient Services & Education Manager at

Safety and Efficacy of Saracatnib in Subjects with Lymphangioleiomyomatosis (SLAM-2)

Dr. N. Tony Eissa at Baylor College of Medicine (main site for this multi-center study)
Women who are 18 years and older who have LAM are eligible to participate in this study. Subjects will be given 125 mg of saracaatnib for up to nine months. The entire duration of the study is 12 months. Seven visits will be required throughout the study.

If you are interested in participating, please contact:

Caryn O. Pope, BSN, RRT, RCP
Clinical Research Coordinator
Baylor College of Medicine - Ben Taub General Hospital
(713) 873-2471 (office)
CLICK HERE for more details about the study.

COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC

David Kwiatkowski, Brigham and Women's Hospital
We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
CLICK HERE for more details.

"BUILD" Biomarker Utility in LAM Diagnosis

Dr. Lisa Young at Vanderbilt University
*Females age 13 and older who have been diagnosed with LAM, either Sporadic LAM or TSC associated LAM
*Please note: Diagnosis of TSC is not required
CLICK HERE for more details


Dr. Francis X. McCormack at University of Cincinnati
Any woman diagnosed with LAM is eligible to participate in the MIDAS trial. It is important that all women with LAM at least contact the study coordinator to discuss the details of the study. NIH Continued funding of this study is dependent on Dr. McCormack and the other site's ability to enroll as many women with LAM as possible in the Multi center International Durability and Safety of Sirolimus in Lymphangioleiomyomatosis Trial (MIDAS Trial).
CLICK HERE for more details

Safety Study of Simvastatin (SOS)

Dr. Vera Krymskaya
CLICK HERE for more details.